ADVERSE O
REACTIONS O
Associated O
With O
Discontinuation O
of O
Treatment O
: O
Twenty O
percent O
( O
1,199/6,145 O
) O
of O
patients O
treated O
with O
PAXIL O
in O
worldwide O
clinical O
trials O
in O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
and O
16.1 O
% O
( O
84/522 O
) O
, O
11.8 O
% O
( O
64/542 O
) O
, O
9.4 O
% O
( O
44/469 O
) O
, O
10.7 O
% O
( O
79/735 O
) O
, O
and O
11.7 O
% O
( O
79/676 O
) O
of O
patients O
treated O
with O
PAXIL O
in O
worldwide O
trials O
in O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
OCD B-Not_AE_Candidate
, O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
PTSD B-Not_AE_Candidate
, O
respectively O
, O
discontinued O
treatment O
due O
to O
an O
adverse O
event O
. O

The O
most O
common O
events O
( O
> O
=1 O
% O
) O
associated O
with O
discontinuation O
and O
considered O
to O
be O
drug O
related O
( O
i.e. O
, O
those O
events O
associated O
with O
dropout O
at O
a O
rate O
approximately O
twice O
or O
greater O
for O
PAXIL O
compared O
to O
placebo O
) O
included O
the O
following O
: O
Major O
Depressive O
Disorder O
OCD O
Panic O
Disorder O
Social O
Anxiety O
Disorder O
Generalized O
Anxiety O
Disorder O
PTSD O
PAXIL O
Placebo O
PAXIL O
Placebo O
PAXIL O
Placebo O
PAXIL O
Placebo O
PAXIL O
Placebo O
PAXIL O
Placebo O
CNS B-NonOSE_AE
Somnolence B-OSE_Labeled_AE
2.3 O
% O
0.7 O
% O
- O
1.9 O
% O
0.3 O
% O
3.4 O
% O
0.3 O
% O
2.0 O
% O
0.2 O
% O
2.8 O
% O
0.6 O
% O
Insomnia B-OSE_Labeled_AE
- O
- O
1.7 O
% O
0 O
% O
1.3 O
% O
0.3 O
% O
3.1 O
% O
0 O
% O
- O
- O
Agitation B-OSE_Labeled_AE
1.1 O
% O
0.5 O
% O
- O
- O
- O
Tremor B-OSE_Labeled_AE
1.1 O
% O
0.3 O
% O
- O
1.7 O
% O
0 O
% O
1.0 O
% O
0.2 O
% O
Anxiety B-OSE_Labeled_AE
- O
- O
- O
1.1 O
% O
0 O
% O
- O
- O
Dizziness B-OSE_Labeled_AE
- O
- O
1.5 O
% O
0 O
% O
1.9 O
% O
0 O
% O
1.0 O
% O
0.2 O
% O
- O
- O
Gastrointestinal B-NonOSE_AE
Constipation B-OSE_Labeled_AE
- O
1.1 O
% O
0 O
% O
- O
- O
Nausea B-OSE_Labeled_AE
3.2 O
% O
1.1 O
% O
1.9 O
% O
0 O
% O
3.2 O
% O
1.2 O
% O
4.0 O
% O
0.3 O
% O
2.0 O
% O
0.2 O
% O
2.2 O
% O
0.6 O
% O
Diarrhea B-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
Dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
- O
- O
Vomiting B-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
1.0 O
% O
0 O
% O
- O
- O
Flatulence B-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
- O
Other O
Asthenia B-OSE_Labeled_AE
1.6 O
% O
0.4 O
% O
1.9 O
% O
0.4 O
% O
2.5 O
% O
0.6 O
% O
1.8 O
% O
0.2 O
% O
1.6 O
% O
0.2 O
% O
Abnormal B-OSE_Labeled_AE
Ejaculationa I-OSE_Labeled_AE
1.6 O
% O
0 O
% O
2.1 O
% O
0 O
% O
4.9 O
% O
0.6 O
% O
2.5 O
% O
0.5 O
% O
- O
- O
Sweating B-OSE_Labeled_AE
1.0 O
% O
0.3 O
% O
- O
1.1 O
% O
0 O
% O
1.1 O
% O
0.2 O
% O
- O
- O
Impotencea B-OSE_Labeled_AE
- O
1.5 O
% O
0 O
% O
- O
- O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
1.0 O
% O
0 O
% O
- O
- O
Where O
numbers O
are O
not O
provided O
the O
incidence O
of O
the O
adverse O
events O
in O
patients O
treated O
with O
PAXIL O
was O
not O
> O
1 O
% O
or O
was O
not O
greater O
than O
or O
equal O
to O
2 O
times O
the O
incidence O
of O
placebo O
. O

a O
. O

Incidence O
corrected O
for O
gender O
. O

Commonly O
Observed O
Adverse O
Events O
: O
Major O
Depressive O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
2 O
) O
were O
: O
Asthenia B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
nervousness B-OSE_Labeled_AE
, O
ejaculatory B-OSE_Labeled_AE
disturbance I-OSE_Labeled_AE
, O
and O
other O
male B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
. O

Obsessive O
Compulsive O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
of O
placebo O
, O
derived O
from O
Table O
3 O
) O
were O
: O
Nausea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
impotence B-OSE_Labeled_AE
, O
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

Panic O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
3 O
) O
were O
: O
Asthenia B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
. O

Social O
Anxiety O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
3 O
) O
were O
: O
Sweating B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
yawn B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
. O

Generalized O
Anxiety O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
4 O
) O
were O
: O
Asthenia B-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

Posttraumatic O
Stress O
Disorder O
: O
The O
most O
commonly O
observed O
adverse O
events O
associated O
with O
the O
use O
of O
paroxetine O
( O
incidence O
of O
5 O
% O
or O
greater O
and O
incidence O
for O
PAXIL O
at O
least O
twice O
that O
for O
placebo O
, O
derived O
from O
Table O
4 O
) O
were O
: O
Asthenia B-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
genital I-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
. O

Incidence O
in O
Controlled O
Clinical O
Trials O
: O
The O
prescriber O
should O
be O
aware O
that O
the O
figures O
in O
the O
tables O
following O
can O
not O
be O
used O
to O
predict O
the O
incidence O
of O
side O
effects O
in O
the O
course O
of O
usual O
medical O
practice O
where O
patient O
characteristics O
and O
other O
factors O
differ O
from O
those O
that O
prevailed O
in O
the O
clinical O
trials O
. O

Similarly O
, O
the O
cited O
frequencies O
can O
not O
be O
compared O
with O
figures O
obtained O
from O
other O
clinical O
investigations O
involving O
different O
treatments O
, O
uses O
, O
and O
investigators O
. O

The O
cited O
figures O
, O
however O
, O
do O
provide O
the O
prescribing O
physician O
with O
some O
basis O
for O
estimating O
the O
relative O
contribution O
of O
drug O
and O
nondrug O
factors O
to O
the O
side O
effect O
incidence O
rate O
in O
the O
populations O
studied O
. O

Major O
Depressive O
Disorder O
: O
Table O
2 O
enumerates O
adverse O
events O
that O
occurred O
at O
an O
incidence O
of O
1 O
% O
or O
more O
among O
paroxetine-treated O
patients O
who O
participated O
in O
short-term O
( O
6-week O
) O
placebo-controlled O
trials O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
20 O
mg O
to O
50 O
mg/day O
. O

Reported O
adverse O
events O
were O
classified O
using O
a O
standard O
COSTART-based O
Dictionary O
terminology O
. O

Table O
2 O
. O

Treatment-Emergent O
Adverse O
Experience O
Incidence O
in O
Placebo-Controlled O
Clinical O
Trials O
for O
Major O
Depressive O
Disordera O
Body O
System O
Preferred O
Term O
PAXIL O
( O
n O
= O
421 O
) O
Placebo O
( O
n O
= O
421 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Headache B-OSE_Labeled_AE
18 O
% O
17 O
% O
Asthenia B-OSE_Labeled_AE
15 O
% O
6 O
% O
Cardiovascular B-NonOSE_AE
Palpitation B-OSE_Labeled_AE
3 O
% O
1 O
% O
Vasodilation B-OSE_Labeled_AE
3 O
% O
1 O
% O
Dermatologic B-NonOSE_AE
Sweating B-OSE_Labeled_AE
11 O
% O
2 O
% O
Rash B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
26 O
% O
9 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
18 O
% O
12 O
% O
Constipation B-OSE_Labeled_AE
14 O
% O
9 O
% O
Diarrhea B-OSE_Labeled_AE
12 O
% O
8 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
6 O
% O
2 O
% O
Flatulence B-OSE_Labeled_AE
4 O
% O
2 O
% O
Oropharynx B-OSE_Labeled_AE
Disorderb I-OSE_Labeled_AE
2 O
% O
0 O
% O
Dyspepsia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Musculoskeletal B-NonOSE_AE
Myopathy B-OSE_Labeled_AE
2 O
% O
1 O
% O
Myalgia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Myasthenia B-OSE_Labeled_AE
1 O
% O
0 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
23 O
% O
9 O
% O
Dizziness B-OSE_Labeled_AE
13 O
% O
6 O
% O
Insomnia B-OSE_Labeled_AE
13 O
% O
6 O
% O
Tremor B-OSE_Labeled_AE
8 O
% O
2 O
% O
Nervousness B-OSE_Labeled_AE
5 O
% O
3 O
% O
Anxiety B-OSE_Labeled_AE
5 O
% O
3 O
% O
Paresthesia B-OSE_Labeled_AE
4 O
% O
2 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
3 O
% O
0 O
% O
Drugged B-OSE_Labeled_AE
Feeling I-OSE_Labeled_AE
2 O
% O
1 O
% O
Confusion B-OSE_Labeled_AE
1 O
% O
0 O
% O
Respiration B-NonOSE_AE
Yawn B-OSE_Labeled_AE
4 O
% O
0 O
% O
Special B-NonOSE_AE
Senses I-NonOSE_AE
Blurred B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
4 O
% O
1 O
% O
Taste B-OSE_Labeled_AE
Perversion I-OSE_Labeled_AE
2 O
% O
0 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Ejaculatory B-OSE_Labeled_AE
Disturbancec I-OSE_Labeled_AE
, O
d O
13 O
% O
0 O
% O
Other O
Male B-OSE_Labeled_AE
Genital I-OSE_Labeled_AE
Disordersc I-OSE_Labeled_AE
, O
e O
10 O
% O
0 O
% O
Urinary B-OSE_Labeled_AE
Frequency I-OSE_Labeled_AE
3 O
% O
1 O
% O
Urination B-OSE_Labeled_AE
Disorderf I-OSE_Labeled_AE
3 O
% O
0 O
% O
Female B-OSE_Labeled_AE
Genital I-OSE_Labeled_AE
Disordersc I-OSE_Labeled_AE
, O
g O
2 O
% O
0 O
% O
a O
. O

Events O
reported O
by O
at O
least O
1 O
% O
of O
patients O
treated O
with O
PAXIL O
are O
included O
, O
except O
the O
following O
events O
which O
had O
an O
incidence O
on O
placebo O
> O
= O
PAXIL O
: O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
CNS B-NonOSE_AE
stimulation I-NonOSE_AE
, O
fever B-NonOSE_AE
, O
increased B-NonOSE_AE
appetite I-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
postural B-NonOSE_AE
hypotension I-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
( O
includes O
mostly O
`` O
cold B-NonOSE_AE
symptoms I-NonOSE_AE
`` O
or O
`` O
URI B-NonOSE_AE
`` O
) O
, O
trauma B-NonOSE_AE
, O
and O
vomiting B-NonOSE_AE
. O

b O
. O

Includes O
mostly O
`` O
lump B-OSE_Labeled_AE
in I-OSE_Labeled_AE
throat I-OSE_Labeled_AE
`` O
and O
`` O
tightness B-OSE_Labeled_AE
in I-OSE_Labeled_AE
throat I-OSE_Labeled_AE
. O
'' O

c O
. O
Percentage O
corrected O
for O
gender O
. O

d O
. O
Mostly O
`` O
ejaculatory B-OSE_Labeled_AE
delay I-OSE_Labeled_AE
. O
'' O

e O
. O
Includes O
`` O
anorgasmia B-OSE_Labeled_AE
, O
'' O
`` O
erectile B-OSE_Labeled_AE
difficulties I-OSE_Labeled_AE
, O
'' O
`` O
delayed B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
/orgasm O
, O
'' O
and O
`` O
sexual B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
, O
'' O
and O
`` O
impotence B-OSE_Labeled_AE
. O
'' O

f O
. O
Includes O
mostly O
`` O
difficulty B-OSE_Labeled_AE
with I-OSE_Labeled_AE
micturition I-OSE_Labeled_AE
`` O
and O
`` O
urinary B-OSE_Labeled_AE
hesitancy I-OSE_Labeled_AE
. O
'' O

g O
. O
Includes O
mostly O
`` O
anorgasmia B-OSE_Labeled_AE
`` O
and O
`` O
difficulty B-OSE_Labeled_AE
reaching I-OSE_Labeled_AE
climax I-OSE_Labeled_AE
/orgasm O
. O
'' O

Obsessive O
Compulsive O
Disorder O
, O
Panic O
Disorder O
, O
and O
Social O
Anxiety O
Disorder O
: O
Table O
3 O
enumerates O
adverse O
events O
that O
occurred O
at O
a O
frequency O
of O
2 O
% O
or O
more O
among O
OCD B-Not_AE_Candidate
patients O
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
12-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
20 O
mg O
to O
60 O
mg/day O
or O
among O
patients O
with O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
10- O
to O
12-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
10 O
mg O
to O
60 O
mg/day O
or O
among O
patients O
with O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
12-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
20 O
mg O
to O
50 O
mg/day O
. O

Table O
3 O
. O

Treatment-Emergent O
Adverse O
Experience O
Incidence O
in O
Placebo-Controlled O
Clinical O
Trials O
for O
Obsessive O
Compulsive O
Disorder O
, O
Panic O
Disorder O
, O
and O
Social O
Anxiety O
Disordera O
Body O
System O
Preferred O
Term O
Obsessive O
Compulsive O
Disorder O
Panic O
Disorder O
Social O
Anxiety O
Disorder O
PAXIL O
( O
n O
= O
542 O
) O
Placebo O
( O
n O
= O
265 O
) O
PAXIL O
( O
n O
= O
469 O
) O
Placebo O
( O
n O
= O
324 O
) O
PAXIL O
( O
n O
= O
425 O
) O
Placebo O
( O
n O
= O
339 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
22 O
% O
14 O
% O
14 O
% O
5 O
% O
22 O
% O
14 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
- O
- O
4 O
% O
3 O
% O
- O
- O
Chest B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
3 O
% O
2 O
% O
- O
- O
- O
- O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
- O
- O
3 O
% O
2 O
% O
- O
- O
Chills B-OSE_Labeled_AE
2 O
% O
1 O
% O
2 O
% O
1 O
% O
- O
- O
Trauma B-OSE_Labeled_AE
- O
- O
- O
- O
3 O
% O
1 O
% O
Cardiovascular B-NonOSE_AE
Vasodilation B-OSE_Labeled_AE
4 O
% O
1 O
% O
- O
- O
- O
- O
Palpitation B-OSE_Labeled_AE
2 O
% O
0 O
% O
- O
- O
- O
- O
Dermatologic B-NonOSE_AE
Sweating B-OSE_Labeled_AE
9 O
% O
3 O
% O
14 O
% O
6 O
% O
9 O
% O
2 O
% O
Rash B-OSE_Labeled_AE
3 O
% O
2 O
% O
- O
- O
- O
- O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
23 O
% O
10 O
% O
23 O
% O
17 O
% O
25 O
% O
7 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
18 O
% O
9 O
% O
18 O
% O
11 O
% O
9 O
% O
3 O
% O
Constipation B-OSE_Labeled_AE
16 O
% O
6 O
% O
8 O
% O
5 O
% O
5 O
% O
2 O
% O
Diarrhea B-OSE_Labeled_AE
10 O
% O
10 O
% O
12 O
% O
7 O
% O
9 O
% O
6 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
9 O
% O
3 O
% O
7 O
% O
3 O
% O
8 O
% O
2 O
% O
Dyspepsia B-OSE_Labeled_AE
- O
- O
- O
- O
4 O
% O
2 O
% O
Flatulence B-OSE_Labeled_AE
- O
- O
- O
- O
4 O
% O
2 O
% O
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
4 O
% O
3 O
% O
2 O
% O
1 O
% O
- O
- O
Vomiting B-OSE_Labeled_AE
- O
- O
- O
- O
2 O
% O
1 O
% O
Musculoskeletal B-NonOSE_AE
Myalgia B-OSE_Labeled_AE
- O
- O
- O
- O
4 O
% O
3 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
24 O
% O
13 O
% O
18 O
% O
10 O
% O
21 O
% O
16 O
% O
Somnolence B-OSE_Labeled_AE
24 O
% O
7 O
% O
19 O
% O
11 O
% O
22 O
% O
5 O
% O
Dizziness B-OSE_Labeled_AE
12 O
% O
6 O
% O
14 O
% O
10 O
% O
11 O
% O
7 O
% O
Tremor B-OSE_Labeled_AE
11 O
% O
1 O
% O
9 O
% O
1 O
% O
9 O
% O
1 O
% O
Nervousness B-OSE_Labeled_AE
9 O
% O
8 O
% O
- O
- O
8 O
% O
7 O
% O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
7 O
% O
4 O
% O
9 O
% O
1 O
% O
12 O
% O
1 O
% O
Agitation B-OSE_Labeled_AE
- O
- O
5 O
% O
4 O
% O
3 O
% O
1 O
% O
Anxiety B-OSE_Labeled_AE
- O
- O
5 O
% O
4 O
% O
5 O
% O
4 O
% O
Abnormal B-OSE_Labeled_AE
Dreams I-OSE_Labeled_AE
4 O
% O
1 O
% O
- O
- O
- O
- O
ConcentrationImpaired B-OSE_Labeled_AE
3 O
% O
2 O
% O
- O
- O
4 O
% O
1 O
% O
Depersonalization B-OSE_Labeled_AE
3 O
% O
0 O
% O
- O
- O
- O
- O
Myoclonus B-OSE_Labeled_AE
3 O
% O
0 O
% O
3 O
% O
2 O
% O
2 O
% O
1 O
% O
Amnesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
- O
- O
- O
- O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Rhinitis B-OSE_Labeled_AE
- O
- O
3 O
% O
0 O
% O
- O
- O
Pharyngitis B-OSE_Labeled_AE
- O
- O
- O
- O
4 O
% O
2 O
% O
Yawn B-OSE_Labeled_AE
- O
- O
- O
- O
5 O
% O
1 O
% O
Special B-NonOSE_AE
Senses I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
4 O
% O
2 O
% O
- O
- O
4 O
% O
1 O
% O
Taste B-OSE_Labeled_AE
Perversion I-OSE_Labeled_AE
2 O
% O
0 O
% O
- O
- O
- O
- O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Ejaculationb I-OSE_Labeled_AE
23 O
% O
1 O
% O
21 O
% O
1 O
% O
28 O
% O
1 O
% O
Dysmenorrhea B-OSE_Labeled_AE
- O
- O
- O
- O
5 O
% O
4 O
% O
Female B-OSE_Labeled_AE
GenitalDisorderb I-OSE_Labeled_AE
3 O
% O
0 O
% O
9 O
% O
1 O
% O
9 O
% O
1 O
% O
Impotenceb B-OSE_Labeled_AE
8 O
% O
1 O
% O
5 O
% O
0 O
% O
5 O
% O
1 O
% O
Urinary B-OSE_Labeled_AE
Frequency I-OSE_Labeled_AE
3 O
% O
1 O
% O
2 O
% O
0 O
% O
- O
- O
Urination B-OSE_Labeled_AE
Impaired I-OSE_Labeled_AE
3 O
% O
0 O
% O
- O
- O
- O
- O
Urinary B-OSE_Labeled_AE
TractInfection I-OSE_Labeled_AE
2 O
% O
1 O
% O
2 O
% O
1 O
% O
- O
- O
a O
. O

Events O
reported O
by O
at O
least O
2 O
% O
of O
OCD B-Not_AE_Candidate
, O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
in O
patients O
treated O
with O
PAXIL O
are O
included O
, O
except O
the O
following O
events O
which O
had O
an O
incidence O
on O
placebo O
> O
= O
PAXIL O
: O
[ O
OCD B-Not_AE_Candidate
] O
: O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
, O
cough B-NonOSE_AE
increased I-NonOSE_AE
, O
depression B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
hyperkinesia B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
paresthesia B-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
, O
rhinitis B-NonOSE_AE
, O
and O
sinusitis B-NonOSE_AE
. O

[ O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
] O
: O
Abnormal B-NonOSE_AE
dreams I-NonOSE_AE
, O
abnormal B-NonOSE_AE
vision I-NonOSE_AE
, O
chest B-NonOSE_AE
pain I-NonOSE_AE
, O
cough B-NonOSE_AE
increased I-NonOSE_AE
, O
depersonalization B-NonOSE_AE
, O
depression B-NonOSE_AE
, O
dysmenorrhea B-NonOSE_AE
, O
dyspepsia B-NonOSE_AE
, O
flu B-NonOSE_AE
syndrome I-NonOSE_AE
, O
headache B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
nervousness B-NonOSE_AE
, O
palpitation B-NonOSE_AE
, O
paresthesia B-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
rash B-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
, O
sinusitis B-NonOSE_AE
, O
taste B-NonOSE_AE
perversion I-NonOSE_AE
, O
trauma B-NonOSE_AE
, O
urination B-NonOSE_AE
impaired I-NonOSE_AE
, O
and O
vasodilation B-NonOSE_AE
. O

[ O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
] O
: O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
depression B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
infection B-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
, O
and O
sinusitis B-NonOSE_AE
. O

b O
. O

Percentage O
corrected O
for O
gender O
. O

Generalized O
Anxiety O
Disorder O
and O
Posttraumatic O
Stress O
Disorder O
: O
Table O
4 O
enumerates O
adverse O
events O
that O
occurred O
at O
a O
frequency O
of O
2 O
% O
or O
more O
among O
GAD B-Not_AE_Candidate
patients O
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
8-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
10 O
mg/day O
to O
50 O
mg/day O
or O
among O
PTSD B-Not_AE_Candidate
patients O
on O
PAXIL O
who O
participated O
in O
placebo-controlled O
trials O
of O
12-weeks O
duration O
in O
which O
patients O
were O
dosed O
in O
a O
range O
of O
20 O
mg/day O
to O
50 O
mg/day O
. O

Table O
4 O
. O

Treatment-Emergent O
Adverse O
Experience O
Incidence O
in O
Placebo-Controlled O
Clinical O
Trials O
for O
Generalized O
Anxiety O
Disorder O
and O
Posttraumatic O
Stress O
Disordera O
Body O
System O
Preferred O
Term O
Generalized O
Anxiety O
Disorder O
Posttraumatic O
Stress O
Disorder O
PAXIL O
( O
n O
= O
735 O
) O
Placebo O
( O
n O
= O
529 O
) O
PAXIL O
( O
n O
= O
676 O
) O
Placebo O
( O
n O
= O
504 O
) O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
14 O
% O
6 O
% O
12 O
% O
4 O
% O
Headache B-OSE_Labeled_AE
17 O
% O
14 O
% O
- O
- O
Infection B-OSE_Labeled_AE
6 O
% O
3 O
% O
5 O
% O
4 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
4 O
% O
3 O
% O
Trauma B-OSE_Labeled_AE
6 O
% O
5 O
% O
Cardiovascular B-NonOSE_AE
Vasodilation B-OSE_Labeled_AE
3 O
% O
1 O
% O
2 O
% O
1 O
% O
Dermatologic B-NonOSE_AE
Sweating B-OSE_Labeled_AE
6 O
% O
2 O
% O
5 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
Nausea B-OSE_Labeled_AE
20 O
% O
5 O
% O
19 O
% O
8 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
11 O
% O
5 O
% O
10 O
% O
5 O
% O
Constipation B-OSE_Labeled_AE
10 O
% O
2 O
% O
5 O
% O
3 O
% O
Diarrhea B-OSE_Labeled_AE
9 O
% O
7 O
% O
11 O
% O
5 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
5 O
% O
1 O
% O
6 O
% O
3 O
% O
Vomiting B-OSE_Labeled_AE
3 O
% O
2 O
% O
3 O
% O
2 O
% O
Dyspepsia B-OSE_Labeled_AE
- O
- O
5 O
% O
3 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
11 O
% O
8 O
% O
12 O
% O
11 O
% O
Somnolence B-OSE_Labeled_AE
15 O
% O
5 O
% O
16 O
% O
5 O
% O
Dizziness B-OSE_Labeled_AE
6 O
% O
5 O
% O
6 O
% O
5 O
% O
Tremor B-OSE_Labeled_AE
5 O
% O
1 O
% O
4 O
% O
1 O
% O
Nervousness B-OSE_Labeled_AE
4 O
% O
3 O
% O
- O
- O
Libido B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
9 O
% O
2 O
% O
5 O
% O
2 O
% O
Abnormal B-OSE_Labeled_AE
Dreams I-OSE_Labeled_AE
3 O
% O
2 O
% O
Respiratory B-NonOSE_AE
System I-NonOSE_AE
Respiratory B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
7 O
% O
5 O
% O
- O
- O
Sinusitis B-OSE_Labeled_AE
4 O
% O
3 O
% O
- O
- O
Yawn B-OSE_Labeled_AE
4 O
% O
- O
2 O
% O
< O
1 O
% O
Special B-NonOSE_AE
Senses I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
2 O
% O
1 O
% O
3 O
% O
1 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Ejaculationb I-OSE_Labeled_AE
25 O
% O
2 O
% O
13 O
% O
2 O
% O
Female B-OSE_Labeled_AE
Genital I-OSE_Labeled_AE
Disorderb I-OSE_Labeled_AE
4 O
% O
1 O
% O
5 O
% O
1 O
% O
Impotenceb B-OSE_Labeled_AE
4 O
% O
3 O
% O
9 O
% O
1 O
% O
a O
. O

Events O
reported O
by O
at O
least O
2 O
% O
of O
GAD B-Not_AE_Candidate
and O
PTSD B-Not_AE_Candidate
in O
patients O
treated O
with O
PAXIL O
are O
included O
, O
except O
the O
following O
events O
which O
had O
an O
incidence O
on O
placebo O
> O
= O
PAXIL O
[ O
GAD B-Not_AE_Candidate
] O
: O
Abdominal B-NonOSE_AE
pain I-NonOSE_AE
, O
back B-NonOSE_AE
pain I-NonOSE_AE
, O
trauma B-NonOSE_AE
, O
dyspepsia B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
and O
pharyngitis B-NonOSE_AE
. O

[ O
PTSD B-Not_AE_Candidate
] O
: O
Back B-NonOSE_AE
pain I-NonOSE_AE
, O
headache B-NonOSE_AE
, O
anxiety B-NonOSE_AE
, O
depression B-NonOSE_AE
, O
nervousness B-NonOSE_AE
, O
respiratory B-NonOSE_AE
disorder I-NonOSE_AE
, O
pharyngitis B-NonOSE_AE
, O
and O
sinusitis B-NonOSE_AE
. O

b O
. O

Percentage O
corrected O
for O
gender O
. O

Dose O
Dependency O
of O
Adverse O
Events O
: O
A O
comparison O
of O
adverse O
event O
rates O
in O
a O
fixed-dose O
study O
comparing O
10 O
, O
20 O
, O
30 O
, O
and O
40 O
mg/day O
of O
PAXIL O
with O
placebo O
in O
the O
treatment O
of O
major O
depressive O
disorder O
revealed O
a O
clear O
dose O
dependency O
for O
some O
of O
the O
more O
common O
adverse O
events O
associated O
with O
use O
of O
PAXIL O
, O
as O
shown O
in O
Table O
5 O
: O
Table O
5 O
. O

Treatment-Emergent O
Adverse O
Experience O
Incidence O
in O
a O
Dose-Comparison O
Trial O
in O
the O
Treatment O
of O
Major O
Depressive O
Disordera O
Body O
System/Preferred O
Term O
Placebo O
PAXIL O
n O
= O
51 O
10 O
mg O
n O
= O
102 O
20 O
mg O
n O
= O
104 O
30 O
mg O
n O
= O
101 O
40 O
mg O
n O
= O
102 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
0.0 O
% O
2.9 O
% O
10.6 O
% O
13.9 O
% O
12.7 O
% O
Dermatology B-NonOSE_AE
Sweating B-OSE_Labeled_AE
2.0 O
% O
1.0 O
% O
6.7 O
% O
8.9 O
% O
11.8 O
% O
Gastrointestinal B-NonOSE_AE
Constipation B-OSE_Labeled_AE
5.9 O
% O
4.9 O
% O
7.7 O
% O
9.9 O
% O
12.7 O
% O
Decreased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
2.0 O
% O
2.0 O
% O
5.8 O
% O
4.0 O
% O
4.9 O
% O
Diarrhea B-OSE_Labeled_AE
7.8 O
% O
9.8 O
% O
19.2 O
% O
7.9 O
% O
14.7 O
% O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
2.0 O
% O
10.8 O
% O
18.3 O
% O
15.8 O
% O
20.6 O
% O
Nausea B-OSE_Labeled_AE
13.7 O
% O
14.7 O
% O
26.9 O
% O
34.7 O
% O
36.3 O
% O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
0.0 O
% O
2.0 O
% O
5.8 O
% O
5.9 O
% O
5.9 O
% O
Dizziness B-OSE_Labeled_AE
3.9 O
% O
6.9 O
% O
6.7 O
% O
8.9 O
% O
12.7 O
% O
Nervousness B-OSE_Labeled_AE
0.0 O
% O
5.9 O
% O
5.8 O
% O
4.0 O
% O
2.9 O
% O
Paresthesia B-OSE_Labeled_AE
0.0 O
% O
2.9 O
% O
1.0 O
% O
5.0 O
% O
5.9 O
% O
Somnolence B-OSE_Labeled_AE
7.8 O
% O
12.7 O
% O
18.3 O
% O
20.8 O
% O
21.6 O
% O
Tremor B-OSE_Labeled_AE
0.0 O
% O
0.0 O
% O
7.7 O
% O
7.9 O
% O
14.7 O
% O
Special B-NonOSE_AE
Senses I-NonOSE_AE
Blurred B-OSE_Labeled_AE
Vision I-OSE_Labeled_AE
2.0 O
% O
2.9 O
% O
2.9 O
% O
2.0 O
% O
7.8 O
% O
Urogenital B-NonOSE_AE
System I-NonOSE_AE
Abnormal B-OSE_Labeled_AE
Ejaculation I-OSE_Labeled_AE
0.0 O
% O
5.8 O
% O
6.5 O
% O
10.6 O
% O
13.0 O
% O
Impotence B-OSE_Labeled_AE
0.0 O
% O
1.9 O
% O
4.3 O
% O
6.4 O
% O
1.9 O
% O
Male B-OSE_Labeled_AE
Genital I-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
0.0 O
% O
3.8 O
% O
8.7 O
% O
6.4 O
% O
3.7 O
% O
a O
. O

Rule O
for O
including O
adverse O
events O
in O
table O
: O
Incidence O
at O
least O
5 O
% O
for O
1 O
of O
paroxetine O
groups O
and O
> O
= O
twice O
the O
placebo O
incidence O
for O
at O
least O
1 O
paroxetine O
group O
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
20 O
, O
40 O
, O
and O
60 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
OCD B-Not_AE_Candidate
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
. O

No O
new O
adverse O
events O
were O
observed O
in O
the O
group O
treated O
with O
60 O
mg O
of O
PAXIL O
compared O
to O
any O
of O
the O
other O
treatment O
groups O
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
10 O
, O
20 O
, O
and O
40 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
, O
except O
for O
asthenia B-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
anxiety B-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

In O
flexible-dose O
studies O
, O
no O
new O
adverse O
events O
were O
observed O
in O
patients O
receiving O
60 O
mg O
of O
PAXIL O
compared O
to O
any O
of O
the O
other O
treatment O
groups O
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
20 O
, O
40 O
, O
and O
60 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
social O
anxiety B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
for O
most O
of O
the O
adverse O
events O
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
20 O
and O
40 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
generalized O
anxiety B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
for O
most O
of O
the O
adverse O
events O
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
, O
except O
for O
the O
following O
adverse O
events O
: O
Asthenia B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

In O
a O
fixed-dose O
study O
comparing O
placebo O
and O
20 O
and O
40 O
mg O
of O
PAXIL O
in O
the O
treatment O
of O
posttraumatic B-Not_AE_Candidate
stress I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
for O
most O
of O
the O
adverse O
events O
, O
there O
was O
no O
clear O
relationship O
between O
adverse O
events O
and O
the O
dose O
of O
PAXIL O
to O
which O
patients O
were O
assigned O
, O
except O
for O
impotence B-OSE_Labeled_AE
and O
abnormal B-OSE_Labeled_AE
ejaculation I-OSE_Labeled_AE
. O

Adaptation O
to O
Certain O
Adverse O
Events O
: O
Over O
a O
4- O
to O
6-week O
period O
, O
there O
was O
evidence O
of O
adaptation O
to O
some O
adverse O
events O
with O
continued O
therapy O
( O
e.g. O
, O
nausea B-OSE_Labeled_AE
and O
dizziness B-OSE_Labeled_AE
) O
, O
but O
less O
to O
other O
effects O
( O
e.g. O
, O
dry B-OSE_Labeled_AE
mouth I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
and O
asthenia B-OSE_Labeled_AE
) O
. O

Male O
and O
Female O
Sexual O
Dysfunction O
With O
SSRIs O
: O
Although O
changes B-NonOSE_AE
in I-NonOSE_AE
sexual I-NonOSE_AE
desire I-NonOSE_AE
, O
sexual O
performance O
, O
and O
sexual O
satisfaction O
often O
occur O
as O
manifestations O
of O
a O
psychiatric B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
they O
may O
also O
be O
a O
consequence O
of O
pharmacologic O
treatment O
. O

In O
particular O
, O
some O
evidence O
suggests O
that O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
can O
cause O
such O
untoward B-OSE_Labeled_AE
sexual I-OSE_Labeled_AE
experiences I-OSE_Labeled_AE
. O

Reliable O
estimates O
of O
the O
incidence O
and O
severity O
of O
untoward B-NonOSE_AE
experiences I-NonOSE_AE
involving I-NonOSE_AE
sexual I-NonOSE_AE
desire I-NonOSE_AE
, O
performance O
, O
and O
satisfaction O
are O
difficult O
to O
obtain O
, O
however O
, O
in O
part O
because O
patients O
and O
physicians O
may O
be O
reluctant O
to O
discuss O
them O
. O

Accordingly O
, O
estimates O
of O
the O
incidence O
of O
untoward B-NonOSE_AE
sexual I-NonOSE_AE
experience I-NonOSE_AE
and O
performance O
cited O
in O
product O
labeling O
, O
are O
likely O
to O
underestimate O
their O
actual O
incidence O
. O

In O
placebo-controlled O
clinical O
trials O
involving O
more O
than O
3,200 O
patients O
, O
the O
ranges O
for O
the O
reported O
incidence O
of O
sexual B-NonOSE_AE
side I-NonOSE_AE
effects I-NonOSE_AE
in O
males O
and O
females O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
OCD B-Not_AE_Candidate
, O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
GAD B-Not_AE_Candidate
, O
and O
PTSD B-Not_AE_Candidate
are O
displayed O
in O
Table O
6 O
. O

Table O
6 O
. O

Incidence O
of O
Sexual O
Adverse O
Events O
in O
Controlled O
Clinical O
Trials O
PAXIL O
Placebo O
n O
( O
males O
) O
1446 O
1042 O
Decreased B-OSE_Labeled_AE
Libido I-OSE_Labeled_AE
6-15 O
% O
0-5 O
% O
Ejaculatory B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
13-28 O
% O
0-2 O
% O
Impotence B-OSE_Labeled_AE
2-9 O
% O
0-3 O
% O
n O
( O
females O
) O
1822 O
1340 O
Decreased B-OSE_Labeled_AE
Libido I-OSE_Labeled_AE
0-9 O
% O
0-2 O
% O
Orgasmic B-OSE_Labeled_AE
Disturbance I-OSE_Labeled_AE
2-9 O
% O
0-1 O
% O
There O
are O
no O
adequate O
and O
well-controlled O
studies O
examining O
sexual B-NonOSE_AE
dysfunction I-NonOSE_AE
with O
paroxetine O
treatment O
. O

Paroxetine O
treatment O
has O
been O
associated O
with O
several O
cases O
of O
priapism B-OSE_Labeled_AE
. O

In O
those O
cases O
with O
a O
known O
outcome O
, O
patients O
recovered O
without O
sequelae O
. O

While O
it O
is O
difficult O
to O
know O
the O
precise O
risk O
of O
sexual B-NonOSE_AE
dysfunction I-NonOSE_AE
associated O
with O
the O
use O
of O
SSRIs O
, O
physicians O
should O
routinely O
inquire O
about O
such O
possible O
side O
effects O
. O

Weight O
and O
Vital O
Sign O
Changes O
: O
Significant O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
may O
be O
an O
undesirable O
result O
of O
treatment O
with O
PAXIL O
for O
some O
patients O
but O
, O
on O
average O
, O
patients O
in O
controlled O
trials O
had O
minimal O
( O
about O
1 O
pound O
) O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
versus O
smaller O
changes O
on O
placebo O
and O
active O
control O
. O

No O
significant O
changes B-NonOSE_AE
in I-NonOSE_AE
vital I-NonOSE_AE
signs I-NonOSE_AE
( O
systolic O
and O
diastolic O
blood O
pressure O
, O
pulse O
and O
temperature O
) O
were O
observed O
in O
patients O
treated O
with O
PAXIL O
in O
controlled O
clinical O
trials O
. O

ECG O
Changes O
: O
In O
an O
analysis O
of O
ECGs O
obtained O
in O
682 O
patients O
treated O
with O
PAXIL O
and O
415 O
patients O
treated O
with O
placebo O
in O
controlled O
clinical O
trials O
, O
no O
clinically O
significant O
changes B-NonOSE_AE
were I-NonOSE_AE
seen I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
ECGs I-NonOSE_AE
of O
either O
group O
. O

Liver O
Function O
Tests O
: O
In O
placebo-controlled O
clinical O
trials O
, O
patients O
treated O
with O
PAXIL O
exhibited O
abnormal B-NonOSE_AE
values I-NonOSE_AE
on I-NonOSE_AE
liver I-NonOSE_AE
function I-NonOSE_AE
tests I-NonOSE_AE
at O
no O
greater O
rate O
than O
that O
seen O
in O
placebo-treated O
patients O
. O

In O
particular O
, O
the O
PAXIL-versus-placebo O
comparisons O
for O
alkaline B-NonOSE_AE
phosphatase I-NonOSE_AE
, O
SGOT O
, O
SGPT O
, O
and O
bilirubin O
revealed O
no O
differences O
in O
the O
percentage O
of O
patients O
with O
marked O
abnormalities I-NonOSE_AE
. O

Hallucinations O
: O
In O
pooled O
clinical O
trials O
of O
immediate-release O
paroxetine O
hydrochloride O
, O
hallucinations B-OSE_Labeled_AE
were O
observed O
in O
22 O
of O
9089 O
patients O
receiving O
drug O
and O
4 O
of O
3187 O
patients O
receiving O
placebo O
. O

Other O
Events O
Observed O
During O
the O
Premarketing O
Evaluation O
of O
PAXIL O
: O
During O
its O
premarketing O
assessment O
in O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
multiple O
doses O
of O
PAXIL O
were O
administered O
to O
6,145 O
patients O
in O
phase O
2 O
and O
3 O
studies O
. O

The O
conditions O
and O
duration O
of O
exposure O
to O
PAXIL O
varied O
greatly O
and O
included O
( O
in O
overlapping O
categories O
) O
open O
and O
double-blind O
studies O
, O
uncontrolled O
and O
controlled O
studies O
, O
inpatient O
and O
outpatient O
studies O
, O
and O
fixed-dose O
, O
and O
titration O
studies O
. O

During O
premarketing O
clinical O
trials O
in O
OCD B-Not_AE_Candidate
, O
panic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
social B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
generalized B-Not_AE_Candidate
anxiety I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
posttraumatic B-Not_AE_Candidate
stress I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
542 O
, O
469 O
, O
522 O
, O
735 O
, O
and O
676 O
patients O
, O
respectively O
, O
received O
multiple O
doses O
of O
PAXIL O
. O

Untoward O
events O
associated O
with O
this O
exposure O
were O
recorded O
by O
clinical O
investigators O
using O
terminology O
of O
their O
own O
choosing O
. O

Consequently O
, O
it O
is O
not O
possible O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
events O
without O
first O
grouping O
similar O
types O
of O
untoward O
events O
into O
a O
smaller O
number O
of O
standardized O
event O
categories O
. O

In O
the O
tabulations O
that O
follow O
, O
reported O
adverse O
events O
were O
classified O
using O
a O
standard O
COSTART-based O
Dictionary O
terminology O
. O

The O
frequencies O
presented O
, O
therefore O
, O
represent O
the O
proportion O
of O
the O
9,089 O
patients O
exposed O
to O
multiple O
doses O
of O
PAXIL O
who O
experienced O
an O
event O
of O
the O
type O
cited O
on O
at O
least O
1 O
occasion O
while O
receiving O
PAXIL O
. O

All O
reported O
events O
are O
included O
except O
those O
already O
listed O
in O
Tables O
2 O
to O
5 O
, O
those O
reported O
in O
terms O
so O
general O
as O
to O
be O
uninformative O
and O
those O
events O
where O
a O
drug O
cause O
was O
remote O
. O

It O
is O
important O
to O
emphasize O
that O
although O
the O
events O
reported O
occurred O
during O
treatment O
with O
paroxetine O
, O
they O
were O
not O
necessarily O
caused O
by O
it O
. O

Events O
are O
further O
categorized O
by O
body O
system O
and O
listed O
in O
order O
of O
decreasing O
frequency O
according O
to O
the O
following O
definitions O
: O
Frequent O
adverse O
events O
are O
those O
occurring O
on O
1 O
or O
more O
occasions O
in O
at O
least O
1/100 O
patients O
( O
only O
those O
not O
already O
listed O
in O
the O
tabulated O
results O
from O
placebo-controlled O
trials O
appear O
in O
this O
listing O
) O
; O
infrequent O
adverse O
events O
are O
those O
occurring O
in O
1/100 O
to O
1/1,000 O
patients O
; O
rare O
events O
are O
those O
occurring O
in O
fewer O
than O
1/1,000 O
patients O
. O

Events O
of O
major O
clinical O
importance O
are O
also O
described O
in O
the O
PRECAUTIONS O
section O
. O

Body O
as O
a O
Whole O
: O
Infrequent O
: O
Allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
, O
face B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
malaise B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
; O
rare O
: O
Adrenergic B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
cellulitis B-OSE_Labeled_AE
, O
moniliasis B-OSE_Labeled_AE
, O
neck B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
peritonitis B-OSE_Labeled_AE
, O
sepsis B-OSE_Labeled_AE
, O
ulcer B-OSE_Labeled_AE
. O

Cardiovascular O
System O
: O
Frequent O
: O
Hypertension B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
; O
infrequent O
: O
Bradycardia B-OSE_Labeled_AE
, O
hematoma B-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
migraine B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
syncope B-OSE_Labeled_AE
; O
rare O
: O
Angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
arrhythmia B-OSE_Labeled_AE
nodal I-OSE_Labeled_AE
, O
atrial B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
, O
cerebral B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
block I-OSE_Labeled_AE
, O
low B-OSE_Labeled_AE
cardiac I-OSE_Labeled_AE
output I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
infarct I-OSE_Labeled_AE
, O
myocardial B-OSE_Labeled_AE
ischemia I-OSE_Labeled_AE
, O
pallor B-OSE_Labeled_AE
, O
phlebitis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
embolus I-OSE_Labeled_AE
, O
supraventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
, O
thrombophlebitis B-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
, O
varicose B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
, O
vascular B-OSE_Labeled_AE
headache I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
extrasystoles I-OSE_Labeled_AE
. O

Digestive O
System O
: O
Infrequent O
: O
Bruxism B-OSE_Labeled_AE
, O
colitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
eructation B-OSE_Labeled_AE
, O
gastritis B-OSE_Labeled_AE
, O
gastroenteritis B-OSE_Labeled_AE
, O
gingivitis B-OSE_Labeled_AE
, O
glossitis B-OSE_Labeled_AE
, O
increased B-OSE_Labeled_AE
salivation I-OSE_Labeled_AE
, O
liver B-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
ulcerative B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
; O
rare O
: O
Aphthous B-OSE_Labeled_AE
stomatitis I-OSE_Labeled_AE
, O
bloody B-OSE_Labeled_AE
diarrhea I-OSE_Labeled_AE
, O
bulimia B-OSE_Labeled_AE
, O
cardiospasm B-OSE_Labeled_AE
, O
cholelithiasis B-OSE_Labeled_AE
, O
duodenitis B-OSE_Labeled_AE
, O
enteritis B-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
impactions I-OSE_Labeled_AE
, O
fecal B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
gum B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
hematemesis B-OSE_Labeled_AE
, O
hepatitis B-OSE_Labeled_AE
, O
ileitis B-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
, O
intestinal B-OSE_Labeled_AE
obstruction I-OSE_Labeled_AE
, O
jaundice B-OSE_Labeled_AE
, O
melena B-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
peptic B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
salivary B-OSE_Labeled_AE
gland I-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
sialadenitis B-OSE_Labeled_AE
, O
stomach B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
tooth B-OSE_Labeled_AE
caries I-OSE_Labeled_AE
. O

Endocrine O
System O
: O
Rare O
: O
Diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
goiter B-OSE_Labeled_AE
, O
hyperthyroidism B-OSE_Labeled_AE
, O
hypothyroidism B-OSE_Labeled_AE
, O
thyroiditis B-OSE_Labeled_AE
. O

Hemic O
and O
Lymphatic O
Systems O
: O
Infrequent O
: O
Anemia B-OSE_Labeled_AE
, O
leukopenia B-OSE_Labeled_AE
, O
lymphadenopathy B-OSE_Labeled_AE
, O
purpura B-OSE_Labeled_AE
; O
rare O
: O
Abnormal B-OSE_Labeled_AE
erythrocytes I-OSE_Labeled_AE
, O
basophilia B-OSE_Labeled_AE
, O
bleeding B-OSE_Labeled_AE
time I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
eosinophilia B-OSE_Labeled_AE
, O
hypochromic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
iron B-OSE_Labeled_AE
deficiency I-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
leukocytosis B-OSE_Labeled_AE
, O
lymphedema B-OSE_Labeled_AE
, O
abnormal B-OSE_Labeled_AE
lymphocytes I-OSE_Labeled_AE
, O
lymphocytosis B-OSE_Labeled_AE
, O
microcytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
monocytosis B-OSE_Labeled_AE
, O
normocytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
thrombocythemia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
. O

Metabolic O
and O
Nutritional O
: O
Frequent O
: O
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
; O
infrequent O
: O
Edema B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
SGOT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
SGPT B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
thirst B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
; O
rare O
: O
Alkaline B-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
bilirubinemia B-OSE_Labeled_AE
, O
BUN B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
creatinine B-OSE_Labeled_AE
phosphokinase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
dehydration B-OSE_Labeled_AE
, O
gamma B-OSE_Labeled_AE
globulins I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
gout B-OSE_Labeled_AE
, O
hypercalcemia B-OSE_Labeled_AE
, O
hypercholesteremia B-OSE_Labeled_AE
, O
hyperglycemia B-OSE_Labeled_AE
, O
hyperkalemia B-OSE_Labeled_AE
, O
hyperphosphatemia B-OSE_Labeled_AE
, O
hypocalcemia B-OSE_Labeled_AE
, O
hypoglycemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
, O
ketosis B-OSE_Labeled_AE
, O
lactic B-OSE_Labeled_AE
dehydrogenase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
non B-OSE_Labeled_AE
- I-OSE_Labeled_AE
protein I-OSE_Labeled_AE
nitrogen I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NPN I-OSE_Labeled_AE
) I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
. O

Musculoskeletal O
System O
: O
Frequent O
: O
Arthralgia B-OSE_Labeled_AE
; O
infrequent O
: O
Arthritis B-OSE_Labeled_AE
, O
arthrosis B-OSE_Labeled_AE
; O
rare O
: O
Bursitis B-OSE_Labeled_AE
, O
myositis B-OSE_Labeled_AE
, O
osteoporosis B-OSE_Labeled_AE
, O
generalized B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
tenosynovitis B-OSE_Labeled_AE
, O
tetany B-OSE_Labeled_AE
. O

Nervous O
System O
: O
Frequent O
: O
Emotional B-OSE_Labeled_AE
lability I-OSE_Labeled_AE
, O
vertigo B-OSE_Labeled_AE
; O
infrequent O
: O
Abnormal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
, O
alcohol B-OSE_Labeled_AE
abuse I-OSE_Labeled_AE
, O
ataxia B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
dyskinesia B-OSE_Labeled_AE
, O
euphoria B-OSE_Labeled_AE
, O
hallucinations B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
hypertonia B-OSE_Labeled_AE
, O
hypesthesia B-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
incoordination B-OSE_Labeled_AE
, O
lack B-OSE_Labeled_AE
of I-OSE_Labeled_AE
emotion I-OSE_Labeled_AE
, O
libido B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
neurosis B-OSE_Labeled_AE
, O
paralysis B-OSE_Labeled_AE
, O
paranoid B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
; O
rare O
: O
Abnormal B-OSE_Labeled_AE
gait I-OSE_Labeled_AE
, O
akinesia B-OSE_Labeled_AE
, O
antisocial B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
aphasia B-OSE_Labeled_AE
, O
choreoathetosis B-OSE_Labeled_AE
, O
circumoral B-OSE_Labeled_AE
paresthesias I-OSE_Labeled_AE
, O
convulsion B-OSE_Labeled_AE
, O
delirium B-OSE_Labeled_AE
, O
delusions B-OSE_Labeled_AE
, O
diplopia B-OSE_Labeled_AE
, O
drug B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
fasciculations B-OSE_Labeled_AE
, O
grand B-OSE_Labeled_AE
mal I-OSE_Labeled_AE
convulsion I-OSE_Labeled_AE
, O
hyperalgesia B-OSE_Labeled_AE
, O
hysteria B-OSE_Labeled_AE
, O
manic B-OSE_Labeled_AE
- I-OSE_Labeled_AE
depressive I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
meningitis B-OSE_Labeled_AE
, O
myelitis B-OSE_Labeled_AE
, O
neuralgia B-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
, O
nystagmus B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
psychotic B-OSE_Labeled_AE
depression I-OSE_Labeled_AE
, O
psychosis B-OSE_Labeled_AE
, O
reflexes B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
reflexes B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
stupor B-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
trismus B-OSE_Labeled_AE
, O
withdrawal B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Respiratory O
System O
: O
Infrequent O
: O
Asthma B-OSE_Labeled_AE
, O
bronchitis B-OSE_Labeled_AE
, O
dyspnea B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
hyperventilation B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
flu I-OSE_Labeled_AE
; O
rare O
: O
Emphysema B-OSE_Labeled_AE
, O
hemoptysis B-OSE_Labeled_AE
, O
hiccups B-OSE_Labeled_AE
, O
lung B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
sputum B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
, O
stridor B-OSE_Labeled_AE
, O
voice B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
. O

Skin O
and O
Appendages O
: O
Frequent O
: O
Pruritus B-OSE_Labeled_AE
; O
infrequent O
: O
Acne B-OSE_Labeled_AE
, O
alopecia B-OSE_Labeled_AE
, O
contact B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
ecchymosis B-OSE_Labeled_AE
, O
eczema B-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
photosensitivity B-OSE_Labeled_AE
, O
urticaria B-OSE_Labeled_AE
; O
rare O
: O
Angioedema B-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
nodosum I-OSE_Labeled_AE
, O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
fungal B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
furunculosis B-OSE_Labeled_AE
; O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
hirsutism B-OSE_Labeled_AE
, O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
seborrhea B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
hypertrophy I-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
sweating B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
, O
vesiculobullous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
. O

Special O
Senses O
: O
Frequent O
: O
Tinnitus B-OSE_Labeled_AE
; O
infrequent O
: O
Abnormality B-OSE_Labeled_AE
of I-OSE_Labeled_AE
accommodation I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
, O
ear B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
keratoconjunctivitis B-OSE_Labeled_AE
, O
mydriasis B-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
; O
rare O
: O
Amblyopia B-OSE_Labeled_AE
, O
anisocoria B-OSE_Labeled_AE
, O
blepharitis B-OSE_Labeled_AE
, O
cataract B-OSE_Labeled_AE
, O
conjunctival B-OSE_Labeled_AE
edema I-OSE_Labeled_AE
, O
corneal B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
deafness B-OSE_Labeled_AE
, O
exophthalmos B-OSE_Labeled_AE
, O
eye B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
glaucoma B-OSE_Labeled_AE
, O
hyperacusis B-OSE_Labeled_AE
, O
night B-OSE_Labeled_AE
blindness I-OSE_Labeled_AE
, O
otitis B-OSE_Labeled_AE
externa I-OSE_Labeled_AE
, O
parosmia B-OSE_Labeled_AE
, O
photophobia B-OSE_Labeled_AE
, O
ptosis B-OSE_Labeled_AE
, O
retinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
visual B-OSE_Labeled_AE
field I-OSE_Labeled_AE
defect I-OSE_Labeled_AE
. O

Urogenital O
System O
: O
Infrequent O
: O
Amenorrhea B-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
cystitis B-OSE_Labeled_AE
, O
dysuria B-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
menorrhagia B-OSE_Labeled_AE
, O
nocturia B-OSE_Labeled_AE
, O
polyuria B-OSE_Labeled_AE
, O
pyuria B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
incontinence I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
urgency I-OSE_Labeled_AE
, O
vaginitis B-OSE_Labeled_AE
; O
rare O
: O
Abortion B-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
atrophy I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
endometrial B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
epididymitis B-OSE_Labeled_AE
, O
female B-OSE_Labeled_AE
lactation I-OSE_Labeled_AE
, O
fibrocystic B-OSE_Labeled_AE
breast I-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
calculus I-OSE_Labeled_AE
, O
kidney B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
leukorrhea B-OSE_Labeled_AE
, O
mastitis B-OSE_Labeled_AE
, O
metrorrhagia B-OSE_Labeled_AE
, O
nephritis B-OSE_Labeled_AE
, O
oliguria B-OSE_Labeled_AE
, O
salpingitis B-OSE_Labeled_AE
, O
urethritis B-OSE_Labeled_AE
, O
urinary B-OSE_Labeled_AE
casts I-OSE_Labeled_AE
, O
uterine B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
urolith B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
. O

Postmarketing O
Reports O
: O
Voluntary O
reports O
of O
adverse O
events O
in O
patients O
taking O
PAXIL O
that O
have O
been O
received O
since O
market O
introduction O
and O
not O
listed O
above O
that O
may O
have O
no O
causal O
relationship O
with O
the O
drug O
include O
acute B-OSE_Labeled_AE
pancreatitis I-OSE_Labeled_AE
, O
elevated B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
function I-OSE_Labeled_AE
tests I-OSE_Labeled_AE
( O
the O
most O
severe O
cases O
were O
deaths B-NonOSE_AE
due O
to O
liver B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
and O
grossly O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
associated O
with O
severe O
liver B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
) O
, O
Guillain B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Barre I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
, O
priapism B-OSE_Labeled_AE
, O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
ADH I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
, O
symptoms O
suggestive O
of O
prolactinemia B-OSE_Labeled_AE
and O
galactorrhea B-OSE_Labeled_AE
; O
extrapyramidal B-NonOSE_AE
symptoms I-NonOSE_AE
which O
have O
included O
akathisia B-NonOSE_AE
, O
bradykinesia B-NonOSE_AE
, O
cogwheel B-NonOSE_AE
rigidity I-NonOSE_AE
, O
dystonia B-NonOSE_AE
, O
hypertonia B-NonOSE_AE
, O
oculogyric B-NonOSE_AE
crisis I-NonOSE_AE
which O
has O
been O
associated O
with O
concomitant O
use O
of O
pimozide O
; O
tremor B-OSE_Labeled_AE
and O
trismus B-OSE_Labeled_AE
; O
status B-OSE_Labeled_AE
epilepticus I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
renal I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
alveolitis I-OSE_Labeled_AE
, O
anaphylaxis B-OSE_Labeled_AE
, O
eclampsia B-OSE_Labeled_AE
, O
laryngismus B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
porphyria B-OSE_Labeled_AE
, O
restless B-OSE_Labeled_AE
legs I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
RLS I-OSE_Labeled_AE
) O
, O
ventricular B-OSE_Labeled_AE
fibrillation I-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
tachycardia I-OSE_Labeled_AE
( O
including O
torsade B-OSE_Labeled_AE
de I-OSE_Labeled_AE
pointes I-OSE_Labeled_AE
) O
, O
thrombocytopenia B-OSE_Labeled_AE
, O
hemolytic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
events O
related O
to O
impaired B-OSE_Labeled_AE
hematopoiesis I-OSE_Labeled_AE
( O
including O
aplastic B-OSE_Labeled_AE
anemia I-OSE_Labeled_AE
, O
pancytopenia B-OSE_Labeled_AE
, O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
aplasia I-OSE_Labeled_AE
, O
and O
agranulocytosis B-OSE_Labeled_AE
) O
, O
vasculitic B-OSE_Labeled_AE
syndromes I-OSE_Labeled_AE
( O
such O
as O
Henoch B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Schonlein I-OSE_Labeled_AE
purpura I-OSE_Labeled_AE
) O
, O
and O
premature B-OSE_Labeled_AE
births I-OSE_Labeled_AE
in O
pregnant B-Not_AE_Candidate
women O
. O

There O
has O
been O
a O
case O
report O
of O
an O
elevated O
phenytoin O
level O
after O
4 O
weeks O
of O
PAXIL O
and O
phenytoin O
coadministration O
. O

There O
has O
been O
a O
case O
report O
of O
severe O
hypotension B-NonOSE_AE
when O
PAXIL O
was O
added O
to O
chronic O
metoprolol O
treatment O
. O

